SS-31
Mitochondria-targeted aromatic-cationic peptide (elamipretide) in clinical development for mitochondrial dysfunction.
Technical Dossier
Batch / Lot Number
—
Testing Status
—
Testing Laboratory
—
Test Date
—
Classification
Mitochondria-targeted aromatic-cationic peptide (elamipretide)
Mechanism / Biological Target
Research Areas
Research Overview
Laboratory Storage & Handling
References
- The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin
Birk AV, et al. Journal of the American Society of Nephrology, 2013.
- Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
Karaa A, et al. Neurology, 2018.
- SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease (review)
Review, 2022.
Available Documentation
- Certificate of AnalysisPending / Not yet available
For Research Use Only
Compounds referenced on Peptide Underground are intended for laboratory and research purposes only. They are not intended to diagnose, treat, cure, or prevent any disease and are not intended for human consumption.